Stages III–IV (n=41) | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
High Wip1 | 4.93 | 1.70–14.3 | 0.0033 | 3.98 | 1.38–11.5 | 0.011 |
Positive p53 | 0.98 | 0.40–2.40 | 0.96 | - | - | - |
High phospho-p53 | 0.35 | 0.10–1.21 | 0.097 | - | - | - |
High nuclear phospho-p38 | 7.86E+07 | 0–Inf | 1.00 | - | - | - |
High cytoplasmic phospho-p38 | 0.48 | 0.20–1.14 | 0.096 | - | - | - |
Age ≥60 | 0.46 | 0.17–1.25 | 0.13 | - | - | - |
Positive peritoneal cytology | 1.03 | 0.30–3.48 | 0.96 | - | - | - |
Residual tumor present | 2.72 | 1.45–6.48 | 0.024 | 2.39 | 0.98–5.79 | 0.055 |
Endometriosis present | 0.82 | 0.34–1.96 | 0.66 | - | - | - |
Lymphadenectmy undone | 1.62 | 0.70–3.75 | 0.26 | - | - | - |
Adjuvant chemotherapy performed | NA | NA | NA | - | - | - |
Pure histology | 1.79 | 0.42–7.66 | 0.43 | - | - | - |